References of "Montalescot, Gilles"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detail2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Montalescot, Gilles; Sechtem, Udo; Achenbach, Stephan et al

in European heart journal (2013), 34(38), 2949-3003

Detailed reference viewed: 97 (0 ULg)
Full Text
Peer Reviewed
See detailEarly versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano, Robert P.; White, Jennifer A.; Bode, Christoph et al

in New England Journal of Medicine [=NEJM] (2009), 360(21), 2176-90

BACKGROUND: Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is ... [more ▼]

BACKGROUND: Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown. METHODS: We compared a strategy of early, routine administration of eptifibatide with delayed, provisional administration in 9492 patients who had acute coronary syndromes without ST-segment elevation and who were assigned to an invasive strategy. Patients were randomly assigned to receive either early eptifibatide (two boluses, each containing 180 microg per kilogram of body weight, administered 10 minutes apart, and a standard infusion > or = 12 hours before angiography) or a matching placebo infusion with provisional use of eptifibatide after angiography (delayed eptifibatide). The primary efficacy end point was a composite of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or the occurrence of a thrombotic complication during percutaneous coronary intervention that required bolus therapy opposite to the initial study-group [less ▲]

Detailed reference viewed: 4 (0 ULg)